Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Mucociliary ClearanceCompleted with results Location: Multiple care centres across the US
Study of QBW276 in adults with CF , protocol number NOVARTIS CQBW 276X2201 QBW276
This study evaluated the safety and tolerability of QBW276, an inhaled drug designed to improve mucus clearance. This study also evaluated how the body processes the drug.
Age:
18 Years and Older
Mutation(s):
No Mutation Requirement
FEV1% Predicted:
40 to 100%
Number of Visits:
6
Length of Participation:
14 days
Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US
Roll-over study of ivacaftor in children with CF who have a CFTR gating mutation (Vertex VX-770-109) , protocol number VX-770-109
This study evaluated the long-term safety of ivacaftor (Kalydeco®) in children with CF. This study was for children who have a CFTR gating mutation and received at least one dose of ivacaftor in the VX11-770-108 study.
2 years to 5 years
One Copy F508del or No Copies F508del
No FEV1 Limit
7
88 weeks
Restore CFTR FunctionEnrolling Location: Multiple care centres across the US
Study of VX-445 triple combination in children 6-11 years old with cystic fibrosis , protocol number VERTEX VX18-445-106
This study will look at the safety and effectiveness of three CFTR modulators when taken in combination: VX-445 (elexacaftor), tezacaftor and ivacaftor. CFTR modulators are drugs intended to help CFTR protein function closer to normal.
6 Years to 11 Years
Two Copies F508del or One Copy F508del
40% or greater
9
32
Mucociliary ClearanceRecruiting Location: Melbourne, Sydney, Newcastle and Brisbane, Australia
A randomised, double blind, study of inhaled alginate oligosaccharide (OligoG) compared to placebo in patients with Cystic Fibrosis , protocol number ORDCF205
This clinical trial is to investigate whether inhaled OligoG dry powder for inhalation (DPI) is effective in the treatment of Cystic Fibrosis, and to further evaluate the safety and tolerability of OligoG DPI. Participants will be treated for 12 weeks with either OligoG, or placebo, while continuing to use any medications that they are already using. Following the results of the 12 week treatment, patients will be offered open label treatment with OligoG for 48 weeks, while continuing to use any medications they are currently using. Only suitable for participants taking continuous or cyclic inhaled antibiotics, and no simultaneous unstable illness. Direct your enquiry to National Office.
18 years and Older
No mutation requirement - Only suitable for participants not taking CFTR modulators
40-90%
12 weeks (followed option of access to Oligog for 1 year, with 5 study visits)
Open-label study of ivacaftor in people with CF who have a non-G551D CFTR gating mutation (Vertex VX-770-112) , protocol number VX-770-112
This study evaluated the long-term safety of ivacaftor (Kelydeco®) in participants who have a non-G551D CFTR gating mutation. This study was for people who had participated in one of the VX11-770-110, VX12-770111 or VX12-770-113 studies.
6 Years and Older
2 years
Mucociliary ClearanceEnrolling Location: Florida, USA
Study of BI 1265162, a mucus clearance drug, in teens and adults with CF. , protocol number BI 1399-0003
This study will look at the safety and effectiveness of BI 1265162, a drug intended to improve the clearance of mucus from the lungs. This study is for people with CF ages 12 and older.
12 Years and Older
40 to 90%
5
7 weeks
ObservationalEnrolling Location: Multiple care centres across the US
Study to evaluate the effects of the triple-combination modulator, elexacaftor/texacaftor/ivacaftor (PROMISE) , protocol number PROMISE
This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in people with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects people with CF across many different aspects of the disease.
Phase 2 study of PTI-808 triple-combination therapy in adults with cystic fibrosis who have at least one copy of the F508del mutation. , protocol number PTI-808-01
This study will look at the safety and tolerability of PTI-808, a modulator intended to help CFTR protein function closer to normal. PTI-808 will be tested in combination with two other modulators, PTI-801 and PTI-428.
Two copies F508del or One Copy F508del
10 weeks
Study of ABBV-3067 and ABBV-2222 in adults with cystic fibrosis who have two copies of the F508del mutation. , protocol number AbbVie ABBV-3067
This study will look at the safety and effectiveness of ABBV-3067, a CFTR modulator intended to help CFTR protein function closer to normal. ABBV-3067 will be tested alone and in combination with another CFTR modulator, ABBV-2222. This study has two parts. In Part 1, participants will be randomly assigned to receive one of the following treatments: the study drug ABBV-3067 alone; both ABBV-3067 and ABBV-2222; or a placebo. In Part 2 of the study, some participants will receive both CFTR modulators ABBV-3067 and ABBV-2222, and some participants will receive a placebo. Researchers will test the effectiveness of ABBV-3067 alone and in combination with ABBV-2222 by measuring changes in lung function and sweat chloride. This study may require lung function tests and/or other measurements.
Two Copies F508del
3 months
Study to evaluate VX-121 in adults 18 years and older with cystic fibrosis , protocol number VERTEX VX-18-121-101
This study will look at the safety, tolerability, and effectiveness of the drug VX-121, a drug intended to help CFTR function closer to normal. This study will take place in two parts. Part 1 is randomized and placebo-controlled. This means that some participants will receive the study drug in combination with tezacaftor and VX-561, and some participants will receive placebo. Part 2 is a randomized, active-comparator trial. This means that some participants will receive the study drug in combination with tezacaftor and VX-561, and some participants will receive placebo in combination with tezacaftor and ivacaftor. In this study, researchers will test the safety and tolerability by monitoring for adverse events. They will test for effectiveness by measuring lung function. They will also monitor sweat chloride and how much of the drug stays in the body. This study may require sweat tests, lung function tests, blood samples and/or other measures.
10
17 weeks